Serum Institute of India in talks to secure a fill-finish deal for the Oxford malaria vaccine in Ghana

23 Apr 2023

Vaccine

The vaccine manufacturer Serum Institute of India is looking to establish fill-finish operations in Ghana for the newly approved Oxford R21 malaria vaccine. The Serum Institute is holding talks with Ghanaian company DEK Vaccines to see how the vaccine could be fill-finished and produced in Ghana, said William Ampofo, the secretary of the presidential committee on vaccine manufacturing and development, in a press conference hosted by the WHO Africa. However, Ampofo did not give any details about the deal so far. Endpoints News reached out to Serum Institute and DEK for more information but did not receive a response by press time.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

SSI Diagnostica A/SNCNH J-Dek LLC

Serum Institute of India Pvt Ltd.

Indications

Malaria

Targets

Drugs

Vaccine (Prothena)

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.